IL1B and Acute hepatitis: CA nanoparticles have also demonstrated the ability to reduce inflammation and apoptosis in acute hepatitis models by decreasing levels of TNF-α, IL-1β, and IL-18, as well as inhibiting NF-κB, NLRP3, and caspase-1, while promoting Bcl-2 levels [32].